Results 21 to 30 of about 11,428,692 (412)

Nontuberculous Mycobacterial Lung Disease in the Patients with Cystic Fibrosis—A Challenging Diagnostic Problem

open access: yesDiagnostics, 2022
Background: Cystic fibrosis (CF) is an autosomal, recessive genetic disorder, caused by a mutation in the cystic fibrosis transmembrane conductance receptor regulator (CFTR) gene.
Dorota Wyrostkiewicz   +6 more
doaj   +1 more source

Interstitial lung disease [PDF]

open access: yesEuropean Respiratory Review, 2014
Interstitial lung diseases are a group of diffuse parenchymal lung disorders associated with substantial morbidity and mortality. Knowledge achieved in recent years has resulted in the publication of the new classification of idiopathic interstitial pneumonias, according to which there are three groups: major, rare and unclassified.
Ulrich Costabel   +10 more
openaire   +4 more sources

Factors Predictive for Immunomodulatory Therapy Response and Survival in Patients with Hypersensitivity Pneumonitis—Retrospective Cohort Analysis

open access: yesDiagnostics, 2022
Hypersensitivity pneumonitis (HP) is one of the interstitial lung diseases with clearly established diagnostic criteria. Nevertheless, pharmacologic treatment recommendations are still lacking. Most specialists use steroids as first-line drugs, sometimes
Katarzyna B. Lewandowska   +11 more
doaj   +1 more source

The Cross-Talk Between Gut Microbiota and Lungs in Common Lung Diseases

open access: yesFrontiers in Microbiology, 2020
Emerging findings indicate there is a vital cross-talk between gut microbiota and the lungs, which is known as gut–lung axis. The gut disturbances in lung diseases including allergy, asthma, chronic obstructive pulmonary disease, cystic fibrosis and lung
Da-Peng Zhang   +5 more
semanticscholar   +1 more source

Tuberculous Pericarditis—Own Experiences and Recent Recommendations

open access: yesDiagnostics, 2022
Tuberculous pericarditis (TBP) accounts for 1% of all forms of tuberculosis and for 1–2% of extrapulmonary tuberculosis. In endemic regions, TBP accounts for 50–90% of effusive pericarditis; in non-endemic, it only accounts for 4%.
Małgorzata Dybowska   +6 more
doaj   +1 more source

Pulmonary Hypertension in the Course of Interstitial Lung Diseases—A Personalised Approach Is Needed to Identify a Dominant Cause and Provide an Effective Therapy

open access: yesDiagnostics, 2023
The prevalence of pulmonary hypertension (PH) complicating interstitial lung diseases (ILDs) is 3.5–15% at an early stage, and up to 90% in ILD patients listed for lung transplantation.
Aneta Kacprzak   +2 more
doaj   +1 more source

Bullous Lung Disease [PDF]

open access: yesWestern Journal of Emergency Medicine, 2013
[West J Emerg Med. 2013;14(5):450–451.]
Goldberg, Corey, Carey, Kathleen E
openaire   +5 more sources

Phenotypes of Sarcoidosis-Associated Pulmonary Hypertension—A Challenging Mystery

open access: yesDiagnostics, 2023
Sarcoidosis has been a well-recognised risk factor for pulmonary hypertension (PH) for a long time, but still, the knowledge about this concatenation is incomplete.
Aneta Kacprzak   +2 more
doaj   +1 more source

Deep Learning Paradigms for Existing and Imminent Lung Diseases Detection: A Review [PDF]

open access: yes, 2023
Diagnosis of lung diseases like asthma, chronic obstructive pulmonary disease, tuberculosis, cancer, etc., by clinicians rely on images taken through various means like X-ray and MRI.
Mittal, Sumit, Vohra, Bhavna
core   +2 more sources

Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs)

open access: yesAnnals of the Rheumatic Diseases, 2020
Interstitial lung diseases (ILDs), which can arise from a broad spectrum of distinct aetiologies, can manifest as a pulmonary complication of an underlying autoimmune and connective tissue disease (CTD-ILD), such as rheumatoid arthritis-ILD and systemic ...
P. Spagnolo   +9 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy